| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2026 | ‡‡‡‡‡ |
|
| 2025 | ‡‡‡‡‡ |
|
| 2024 | ‡‡‡‡‡ |
|
| 2023 | ‡‡‡‡‡ |
|
| 2023 | 2024 | 2025 | Q'25 | |
|---|---|---|---|---|
| Cash | 5.74 | 8.71 | 17.80 | 6.69 |
| Receivables | 3.41 | 0.15 | 0.26 | 0.35 |
| Inventory | — | — | — | — |
| Other | — | — | — | — |
| 9.15 | 8.87 | 18.06 | 7.03 |
| 2023 | 2024 | 2025 | Q'25 | |
|---|---|---|---|---|
| Payables | 4.71 | 4.03 | 6.94 | 10.33 |
| ST’ Debt | 43.06 | 45.66 | 50.92 | 76.38 |
| Other | — | — | — | — |
| 49.60 | 52.09 | 62.98 | 88.36 |
| 10y | 5y | 3y | |
| Sales | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | — | ‡‡‡ | ‡‡‡ |
| Earnings | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | — | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
126.25
|
| ’24 | — | — | — | — |
126.97
|
| ’23 | — | 74.70 | — | 52.63 |
127.33
|
| ’22 | — | 58.50 | — | 63.64 |
123.16
|
| ’21 | — | 62.04 | — | — |
123.16
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | 22.20 | — | — |
22.20
|
| ’24 | — | 10.53 | — | (10.07) |
10.53
|
| ’23 | — | (8.16) | — | (5.64) |
(8.16)
|
| ’22 | — | (25.21) | — | (12.28) |
(25.21)
|
| ’21 | — | 5.32 | — | — |
(2.30)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | 22.20 | — | — |
5.31
|
| ’24 | — | 10.53 | — | (12.64) |
(4.39)
|
| ’23 | — | (8.16) | — | (12.99) |
(17.24)
|
| ’22 | — | (25.21) | — | (12.28) |
(25.44)
|
| ’21 | — | 5.32 | — | — |
(2.30)
|
| Mar | Jun | Sep | Dec | Year | |
|---|---|---|---|---|---|
| ’26 | — | — | — | — |
—
|
| ’25 | — | — | — | — |
0.42
|
| ’24 | — | — | — | — |
0.31
|
| ’23 | — | 0.20 | — | 0.09 |
0.32
|
| ’22 | — | 0.19 | — | 0.11 |
0.31
|
| ’21 | — | 0.15 | — | — |
0.18
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | 4.52 | 1.19 | 1.00 | — | — | — |
Low Price
|
| — | — | — | — | — | — | — | 7.35 | 13.76 | 2.97 | — | — | — |
High Price
|
| — | — | — | — | — | — | 46 | 62 | 70 | 76 | — | — | — |
Employees
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | 2.68 | 2.05 | 1.81 | 1.66 | — | — | — |
Revenue/Emp
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 123.16 | 127.33 | 126.97 | 126.25 | ‡‡‡‡‡ | — | — |
Revenue
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | 17.01% | 15.80% | 15.56% | 19.79% | — | — | — |
Gross Margin
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.98 | 6.27 | 6.39 | 9.34 | — | — | — |
EBT
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 5.67% | 4.93% | 5.03% | 7.40% | ‡‡‡ | — | — |
EBT Margin
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡ | 4.54 | 3.92 | 4.20 | 5.67 | ‡‡‡‡‡ | — | — |
Net Income
|
| — | — | — | — | — | — | 0.38 | 0.56 | 0.69 | 0.74 | — | — | — |
Depreciation
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 9.85 | 10.19 | 9.50 | 9.25 | ‡‡‡‡‡ | — | — |
Revenue/Sh
|
| — | — | — | — | ‡‡‡‡ | ‡‡‡‡ | 0.31 | 0.32 | 0.31 | 0.42 | ‡‡‡‡‡ | — | — |
Earnings/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.02) | (0.65) | 0.79 | 1.63 | ‡‡‡‡ | — | — |
Cash Flow/Sh
|
| — | — | — | — | ‡‡‡ | ‡‡‡ | (0.02) | (0.73) | (1.12) | (1.24) | ‡‡‡ | — | — |
Capex/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.04) | (1.38) | (0.33) | 0.39 | — | — | — |
Free CF/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.51 | 1.60 | 2.12 | 2.47 | ‡‡‡‡ | — | — |
Book Value/Sh
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 12.50 | 12.50 | 13.36 | 13.64 | ‡‡‡‡‡ | — | — |
Shares
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.51 | 10.51 | 3.53 | 3.07 | ‡‡‡‡ | — | — |
PE Ratio
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.34 | 0.34 | 0.11 | 0.10 | ‡‡‡ | — | — |
PS Ratio
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.22 | 4.22 | 1.00 | 0.73 | ‡‡‡ | — | — |
PB Ratio
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.65 | 0.65 | 0.39 | 0.35 | ‡‡‡‡ | — | — |
EV/Sales
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (3.15) | (3.15) | (4.13) | 7.40 | — | — | — |
EV/FCF
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (25.21) | (8.16) | 10.53 | 22.20 | ‡‡‡‡‡ | — | — |
Op' Cash Flow
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (0.23) | (9.08) | (14.93) | (16.89) | — | — | — |
Capex
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | (25.44) | (17.24) | (4.39) | 5.31 | ‡‡‡‡‡ | — | — |
FCF
|
| — | — | — | — | — | ‡‡‡‡‡ | (56.80) | (40.44) | (43.22) | (44.92) | — | — | — |
Working Cap'
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 73.90 | 82.76 | 76.47 | 81.46 | — | — | — |
Total Debt
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 70.43 | 77.02 | 67.75 | 63.65 | — | — | — |
Net Debt
|
| — | — | — | — | ‡‡‡‡‡ | ‡‡‡‡‡ | 18.93 | 20.02 | 28.39 | 33.71 | — | — | — |
Sh' Equity
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | 4.26% | 3.53% | 3.64% | 4.49% | — | — | — |
ROA
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | 3.90% | 4.09% | 3.91% | 6.34% | — | — | — |
ROIC
|
| — | — | — | — | ‡‡‡ | ‡‡‡‡‡ | 25.17% | 20.13% | 17.35% | 18.27% | — | — | — |
ROE
|
Lead Real Estate Co., Ltd. (LRE), a micro-cap Chinese property developer, stands out as a beacon of resilience in a battered sector reeling from Beijing’s “three red lines” policy, Evergrande’s collapse, and slumping sales. While peers crumbled, LRE has stabilized revenue at $120-130 million through 2025, boosted gross margins to nearly 20%, and flipped free cash flow positive at $5.3 million—all with a rock-solid balance sheet featuring modest debt and sky-high ROE of 18%. Trading at dirt-cheap valuations (P/E 3.1x, PS 0.10x), the stock languishes 60% below 2025 highs, screaming undervaluation amid ADR illiquidity and China skepticism.
The real excitement? Analysts forecast a jaw-dropping 1,700% revenue explosion to $2.25 billion in 2026, propelled by a potential mega-project, merger, or REIT pivot, catapulting EPS to $1.47 and net income to $352 million. This transformative leap builds on 2025’s profitability surge—EBT up 46%, book value per share up 16%—positioning LRE for explosive rerating in a sector poised for stimulus-driven recovery.
With pristine fundamentals decoupled from price action and massive upside skew, LRE offers turnaround potential for patient growth seekers eyeing 50-100%+ returns as China real estate rebounds.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.